FDA approves Invokana to reduce risk of CV events in adults with type 2 diabetes and CV disease Oct. 31, 2018
Dual GLP-1/GIP agonist LY-3298176 superior to GLP-1 agonist dulaglutide for diabetes control Oct. 30, 2018
New phase Ib/IIa study explores use of AG-019 for treatment of early-onset type 1 diabetes Oct. 29, 2018
Novo Nordisk reports PIONEER 8 topline results with oral semaglutide in type 2 diabetes Oct. 29, 2018
RSS